

#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Nahass 1



Section 1. Identifying Information	ation		
1. Given Name (First Name) Ronald	2. Surname (Last Name) Nahass	)	3. Date 30-June-2015
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Autho	or's Name
5. Manuscript Title Sofosbuvir with GS-5816 in treatment-na	aïve genotype 1-6 hepa	atitis C patients: a rando	mized, Phase 2 trial
6. Manuscript Identifying Number (if you known M15-1000	ow it)		
Section 2. The Work Under Co	onsideration for Pub	olication	
Did you or your institution <b>at any time</b> received any aspect of the submitted work (including statistical analysis, etc.)?		. , .	•
Are there any relevant conflicts of interes	st? ✓ Yes No	)	
If yes, please fill out the appropriate info	•	nave more than one enti	ty press the "ADD" button to add a row.
Excess rows can be removed by pressing		lan Financial	
Name of Institution/Company	Grant? Personal N	Ion-Financial Other?	Comments
Gilead	<b>V</b>		
Section 3. Relevant financial a	activities outside the	e submitted work.	
Place a check in the appropriate boxes ir of compensation) with entities as described clicking the "Add +" box. You should rep	bed in the instructions.	Use one line for each er	itity; add as many lines as you need by
Are there any relevant conflicts of interes	st? ✓ Yes No	)	
If yes, please fill out the appropriate info	rmation below.		
Name of Entity	Grant? Personal N	Ion-Financial Other?	Comments
Janssen	<b>V</b>		
Merck	✓		
Abbvie	<b>✓</b>		

Nahass 2



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
MS	<b>✓</b>	<b>✓</b>				
Section 4. Intellectual Proper	ty Pate	ents & Co	pyrights			
Do you have any patents, whether plan	ned, pend	ing or issue	ed, broadly releva	nt to the	work?  Yes ✓ No	
Section 5. Relationships not	covered	above				
Are there other relationships or activities				influenced	d, or that give the appearance of	
potentially influencing, what you wrote	in the sub	omitted wo	rk?			
Yes, the following relationships/con	ditions/cii	rcumstance	es are present (exp	olain belo	w):	
No other relationships/conditions/c	ircumstan	ces that pr	esent a potential	conflict of	interest	
At the time of manuscript acceptance, j					•	ments.
On occasion, journals may ask authors t	o aisciose	turtner inte	ormation about re	eportea re	elationsnips.	
Carting						
Section 6. Disclosure Stateme	ent					
Based on the above disclosures, this for below.	m will aut	omatically	generate a disclo	sure state	ment, which will appear in the box	X
Dr. Nahass reports grants from Gilead,	during the	e conduct c	of the study; grant	ts and per	sonal fees from Janssen, grants ar	nd
personal fees from Merck, grants and p work; .	_			•	_	

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Nahass 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent



Section 1.	Identifying Inforn	nation				
1. Given Name (Fi William	rst Name)	2. Surname Towner	(Last Nam	e)		3. Date 30-June-2015
4. Are you the cor	responding author?	Yes	✓ No	Correspond Gregory T	_	
5. Manuscript Title Sofosbuvir with	e GS-5816 in treatment-	naïve genoty	pe 1-6 hep	oatitis C patients	s: a rando	mized, Phase 2 trial
6. Manuscript Ide	ntifying Number (if you k	now it)				
Section 2.	The Work Under C	onsideratio	on for Pu	blication		
	submitted work (including					ent, commercial, private foundation, etc.) for udy design, manuscript preparation,
· · · · · · · · · · · · · · · · · · ·	evant conflicts of inter	est? 🗸 Ye	s N	lo		
	out the appropriate inf be removed by pressir			have more than	one enti	ty press the "ADD" button to add a row.
Name of Institut	, , , , , , , , , , , , , , , , , , ,	Grant? P		Non-Financial Support?	Other?	Comments
Gilead		<b>✓</b>				Paid to Institution
Section 3.	Relevant financial	activities o	utside tl	ne submitted	work.	
of compensation	n) with entities as descr	ribed in the ir	structions	s. Use one line fo	or each er	cial relationships (regardless of amount ntity; add as many lines as you need by e 36 months prior to publication.
Are there any rel	evant conflicts of inter	est? 🗸 Ye	s N	lo		
If yes, please fill o	out the appropriate inf	ormation bel	ow.			
Name of Entity		Grant	ersonal Fees	Non-Financial Support?	Other?	Comments
BMS		<b>✓</b>				Paid to Institution
/iiV		<b>✓</b>				Paid to Institution
/ertex		✓				Paid to Institution



Name of Entity	Grant? Personal Fees?	Non-Financial Support?	Other? C	omments	
Pfizer	<b>✓</b>		Paid	d to Institution	
Merck	<b>✓</b>		Paid	d to Institution	
Section 4					
Section 4. Intellectual Propert	ty Patents & Co	pyrights			
Do you have any patents, whether plann	ned, pending or issu	ed, broadly releva	nt to the wor	rk? ☐ Yes ✓ No	
Section 5. Relationships not c	covered above				
Are there other relationships or activities potentially influencing, what you wrote in Yes, the following relationships/conditions/cir/ No other relationships/conditions/cir/ At the time of manuscript acceptance, jo On occasion, journals may ask authors to	in the submitted wo ditions/circumstanc rcumstances that pr ournals will ask auth	ork? es are present (expresent a potential of the confirm and	olain below): conflict of int d, if necessary	erest v, update their disclosure sta	
Section 6. Disclosure Stateme	nt				
Based on the above disclosures, this form below.	n will automatically	generate a disclos	sure stateme	nt, which will appear in the k	юх
Dr. Towner reports grants from Gilead, overtex, grants from Pfizer, grants from N			ts from BMS,	grants from ViiV, grants fron	n



#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Brainard 1



Section 1.	Identifying Inform	nation			
1. Given Name (Fi Diana	rst Name)	2. Surname (Last Name Brainard	e)	3. Date 30-June-2015	
4. Are you the cor	responding author?	Yes ✓ No	Corresponding Author's Nat Greg Everson	ame	
5. Manuscript Title "Sofosbuvir with		-naïve genotype 1-6 he	oatitis C patients: a randomize	ed, Phase 2 trial"	
6. Manuscript Ider M15-1000	ntifying Number (if you kr	now it)			
Section 2.	The Work Under C	onsideration for Pu	olication		
any aspect of the s statistical analysis,	ubmitted work (including	g but not limited to grants	, data monitoring board, study de	ommercial, private foundation, etc esign, manuscript preparation,	.) 101
Section 3.	Relevant financial	activities outside th	e submitted work.		
of compensation clicking the "Add Are there any rel	) with entities as descri	ibed in the instructions port relationships that est?	. Use one line for each entity; a were <b>present during the 36 m</b>	lationships (regardless of amou add as many lines as you need <b>nonths prior to publication</b> .	
Name of Entity		Grant? Personal Fees?	Non-Financial Support? Other? Con	mments	
Gilead Sciences			✓ emplo	oyee, share holder	
Section 4.	Intellectual Proper	rty Patents & Copy	vrights		
Do you have any	patents, whether plan	ned, pending or issued	, broadly relevant to the work?	? ☑ Yes 🗸 No	

Brainard 2



Section 5. Polationships not sovered above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Brainard reports other from Gilead Sciences, outside the submitted work; .

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Brainard 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Davis 1



Section 1. Identifying Information	ation		
Given Name (First Name)  Mitchell	2. Surname (Las Davis	st Name)	3. Date 30-June-2015
4. Are you the corresponding author?	Yes ✓	No Correspond Everson	ding Author's Name
5. Manuscript Title Sofosbuvir with GS- 5816 in treatment-n	aive genotype	1-6 hepatitis C patient	s: a randomized Phase 2 trial.
6. Manuscript Identifying Number (if you known M15-1000	ow it)		
Section 2. The Work Under Co	nsideration f	or Publication	
			(government, commercial, private foundation, etc.) for g board, study design, manuscript preparation,
Are there any relevant conflicts of interes	st? ✓ Yes	No	
		•	n one entity press the "ADD" button to add a row
Excess rows can be removed by pressing			
Name of Institution/Company	Grant? Perso	2 2	Other? Comments
Gilead Sciences	<b>✓</b>		Research support, Advisory boards, Speaker's Bureau
Section 3. Relevant financial a	ctivities outs	ide the submitted	work.
of compensation) with entities as describ	oed in the instru	ıctions. Use one line fo	ave financial relationships (regardless of amount or each entity; add as many lines as you need by luring the 36 months prior to publication.
Are there any relevant conflicts of interes		No	
If yes, please fill out the appropriate info	rmation below.		
Name of Entity	Grant? Perso		Other? Comments
AbbVie Pharmaceuticals	<b>V</b>		Research supports, Advisory boards, Speaker's bureau
lanssen	<b>✓</b>		Research support, Speaker's bureau

Davis 2



Section 4. Intellectual Property Patents & Copyrights
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Volume
Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Davis reports grants and other from Gilead Sciences, during the conduct of the study; grants and other from AbbVie Pharmaceuticals, grants and other from Janssen, outside the submitted work; .

### **Evaluation and Feedback**

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$ 

Davis 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

McNally 1



Section 1.	Identifying Inform	ation			
1. Given Name (Fi John	rst Name)	2. Surname (Last Name) McNally		3. Date 30-June-2015	
4. Are you the cor	responding author?	Yes ✓ No	Corresponding Gregory T Eve	Author's Name	
5. Manuscript Title Sofosbuvir with		naïve genotype 1-6 hepat	itis C patients: a	randomized, Phase 2 trial	
6. Manuscript Ider M15-1000	ntifying Number (if you kn	now it)			
	l				
Section 2.	The Work Under Co	onsideration for Publ	ication		
any aspect of the s statistical analysis, Are there any rel If yes, please fill o	ubmitted work (including etc.)? evant conflicts of intere	but not limited to grants, cest?  Yes  No prmation below. If you ha	lata monitoring bo	rernment, commercial, private ard, study design, manuscript e entity press the "ADD" bu	preparation,
Name of Institut		Grant? Personal No	on-Financial Support	her? Comments	
Gilead Sciences, Inc				I am an employee of G	ilead Sciences,
Section 3.	Relevant financial	activities outside the	submitted wo	rk.	
of compensation clicking the "Add Are there any rel	) with entities as descri	bed in the instructions. Uport relations his week	Jse one line for ea	financial relationships (reg ach entity; add as many ling <b>ng the 36 months prior to</b>	es as you need by
Section 4.	Intellectual Proper	ty Patents & Copyr	ights		
Do you have any	patents, whether plan	ned, pending or issued, b	oroadly relevant t	o the work? Yes	No

McNally 2



Section 5.	Deletionaline not covered above
	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
✓ Yes, the follow	wing relationships/conditions/circumstances are present (explain below):
No other rela	tionships/conditions/circumstances that present a potential conflict of interest
I am an empolye	e and stock holder in Gilead Sciences, Inc.
On occasion, jou	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Dr. McNally repo	orts and I am an empolyee and stock holder in Gilead Sciences, Inc

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

McNally 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Rabinovitz 1



Section 1.	dentifying Inform	ation		
1. Given Name (First Mordechai	Name)	2. Surname (Last Name) Rabinovitz		Date -July-2015
4. Are you the corres	sponding author?	Yes ✓ No	Corresponding Author's Name Dr. Everson	
5. Manuscript Title Sofosbuvir with GS	5-5816 in treatment-n	aïve genotype 1-6 hepatit	is C patients: a randomized, Ph	nase 2 trial
6. Manuscript Identii M15-1000	fying Number (if you kn	ow it)		
			-	
Section 2.	he Work Under Co	onsideration for Public	ation	
any aspect of the sub statistical analysis, et	mitted work (including	but not limited to grants, da	a third party (government, comme ta monitoring board, study design	ercial, private foundation, etc.) for n, manuscript preparation,
Section 3.	Relevant financial a	activities outside the s	ubmitted work.	
of compensation) v clicking the "Add +	with entities as descri	bed in the instructions. Us port relationships that wer	ether you have financial relatio e one line for each entity; add a e <b>present during the 36 mon</b> t	as many lines as you need by
Section 4.	ntellectual Proper	ty Patents & Copyric	hts	
Do you have any pa	atents, whether planr	ned, pending or issued, br	oadly relevant to the work?	Yes ✓ No

Rabinovitz 2



Soction F	
Section 5.	elationships not covered above
	tionships or activities that readers could perceive to have influenced, or that give the appearance of ng, what you wrote in the submitted work?
Yes, the followin	g relationships/conditions/circumstances are present (explain below):
✓ No other relation	nships/conditions/circumstances that present a potential conflict of interest
	script acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements Is may ask authors to disclose further information about reported relationships.
Section 6. Di	isclosure Statement
Based on the above below.	disclosures, this form will automatically generate a disclosure statement, which will appear in the box

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Rabinovitz 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Chung 1



Section 1.	Identifying Inforr	mation						
1. Given Name (Fi Raymond	irst Name)	2. Surname (Last I Chung	Name)	3. Date 30-June-2015				
4. Are you the co	responding author?	✓ Yes No	✓ Yes No					
5. Manuscript Titl Sofosbuvir with	e GS-5816 in treatment-	naïve genotype 1-6	hepatitis C patient	s: a randomize	ed, Phase 2 trial			
6. Manuscript Ide	ntifying Number (if you k	now it)						
Section 2.	The Work Under C	Consideration for	· Publication					
any aspect of the s statistical analysis, Are there any re	submitted work (includin	g but not limited to g			ommercial, private foundation, etc.) fo design, manuscript preparation,			
Section 3.	Relevant financia	activities outsid	e the submitted	work.				
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .  Are there any relevant conflicts of interest? Yes No  If yes, please fill out the appropriate information below.								
Name of Entity		Grant? Person	al Non-Financial	Other? Co	omments			
Gilead Sciences		<b>✓</b>		Clini	ical Trial			
Mass Biologics		<b>✓</b>		Clini	ical Trial			
/ertex		<b>✓</b>		Clini	ical Trial			
Merck		<b>✓</b>		Clini	ical Trial			
Abbyie				Clini	ical Trial			

Chung 2



Section 4. Intellectual Property Patents & Copyrights
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo
Section 5.  Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Chung reports grants from Gilead Sciences, grants from Mass Biologics, grants from Vertex, grants from Merck, personal fees from Abbvie, personal fees from Enanta, personal fees from Idenix, outside the submitted work; .

### **Evaluation and Feedback**

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$ 

Chung 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Tran 1



Section 1. Identifying Inform	mation						
1. Given Name (First Name) Tram	2. Surname (Last Name) Tran		3. Date 30-June-2015				
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Autho					
5. Manuscript Title Sofosbuvir with GS-5816 in treatment-naïve genotype 1-6 hepatitis C patients: a randomized, Phase 2 trial							
6. Manuscript Identifying Number (if you k	know it)	_					
Section 2. The Work Under (	Consideration for Publi	cation					
Did you or your institution <b>at any time</b> recany aspect of the submitted work (includin statistical analysis, etc.)?  Are there any relevant conflicts of inte	g but not limited to grants, darrest?  Yes  No	ata monitoring board, stu	udy design, manuscript preparation,				
If yes, please fill out the appropriate information below. If you have more than one entity press the "ADD" button to add a row. Excess rows can be removed by pressing the "X" button.							
Name of Institution/Company	Grant	n-Financial Other?	Comments				
Gilead Sciences	<b>✓</b>						
Section 3. Relevant financia	l activities outside the	submitted work.					
Place a check in the appropriate boxes of compensation) with entities as descricking the "Add +" box. You should read there any relevant conflicts of intelling the second propriate in the second pro	ribed in the instructions. Useport relationships that we rest?   Yes  No	se one line for each er	ntity; add as many lines as you need	l by			
Name of Entity	Grant	n-Financial Other?	Comments				
Gilead Sciences	<b>✓</b>						

Tran 2



Section 4. Intellectual Property Patents & Copyrights
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes V
Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Tran reports grants from Gilead Sciences, during the conduct of the study; grants and personal fees from Gilead Sciences, outside the submitted work; .

### **Evaluation and Feedback**

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$ 

Tran 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent



	I					
Section 1.	Identifying Inform	ation				
1. Given Name (Fi	rst Name)	2. Surname (Last I Everson	lame)		3. Date 07-August-2015	
4. Are you the cor	responding author?	✓ Yes No	)			
5. Manuscript Title Sofosbuvir with randomized trial	velpatasvir in treatment	t-naïve non-cirrho	tic patients with ge	notype 1-	6 hepatitis C virus infection: a	
6. Manuscript Ider M15-1000	ntifying Number (if you kn	ow it)				
	ı					
Section 2.	The Work Under Co	onsideration for	Publication			
	ubmitted work (including				ent, commercial, private foundation, etc.) for udy design, manuscript preparation,	
=	evant conflicts of intere	est? 🗸 Yes	No			
	out the appropriate info		you have more thar	n one enti	ity press the "ADD" button to add a row.	
Name of Institut	ion/Company	Grant? Person		Other?	Comments	
Gilead		<b>✓</b>			Research Grant for the Clinical Trial	
Section 3.	Relevant financial	activities outsid	e the submitted	work.		
of compensation	) with entities as descri	bed in the instruct	ions. Use one line f	or each er	cial relationships (regardless of amount ntity; add as many lines as you need by e 36 months prior to publication.	
Are there any relevant conflicts of interest?						
If yes, please fill out the appropriate information below.						
Name of Entity		Grant? Person		Other?	Comments	
Gilead		<b>✓</b>			Research Grants for other clinical trials; Advisory Board honoraria	
Abbvie					Research Grants for other clinical trials; Advisory Board honoraria	



Name of Entity	Grant	Personal Fees?	Non-Financial Support?	Other?	Comments
Merck	<b>√</b>	<b>✓</b>			Research Grants for other clinical trials; Advisory Board honoraria
BMS	<b>✓</b>	<b>√</b>			Research Grants for other clinical trials; Advisory Board honoraria
Janssen	<b>✓</b>	<b>✓</b>			Research Grants for other clinical trials; Advisory Board honoraria
Section 4. Intellectual P					
Do you have any patents, whether If yes, please fill out the appropriation Excess rows can be removed by p	ite information	below. If yo	•		work?
Patent?	Pending ?	ued ? Licens	Royalties?	License	e? Comments
Several for liver function diagnostics	<b>✓</b>	<b>√</b>		HepQuant	LLC 6 patents issued, several pending - with University of Colorado.
Section 5. Relationship	s not covered	d above			
Are there other relationships or ac potentially influencing, what you				influence	d, or that give the appearance of
Yes, the following relationships/conditions/circumstances are present (explain below):  No other relationships/conditions/circumstances that present a potential conflict of interest					
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements.  On occasion, journals may ask authors to disclose further information about reported relationships.					

on occasion, journals may ask authors to disclose further information about reported relationships.

#### Section 6.

#### **Disclosure Statement**

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Everson reports grants from Gilead, during the conduct of the study; grants and personal fees from Gilead, grants and personal fees from Abbvie, grants and personal fees from Merck, grants and personal fees from BMS, grants and personal fees from Janssen, outside the submitted work; In addition, Dr. Everson has a several patents for liver function diagnostics with exclusive licensing to HepQuant LLC and royalty payments to University of Colorado and Dr. Everson.

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Doehle 1



Section 1.	Identifying Inform	nation				
1. Given Name (Fir Brian		2. Surname (Last Na Doehle	me)		3. Date 19-August-	-2015
4. Are you the cor	responding author?	Yes ✓ No Corresponding Author's Name Gregory T Everson			ame	
5. Manuscript Title Sofosbuvir with velpatasvir in treatment-naïve non-cirrhotic patients with genotype 1-6 hepatitis C virus infection: a randomized trial						
6. Manuscript Ider M15-1000	ntifying Number (if you kr	now it)				
Section 2.	The Work Under Co	onsideration for P	ublication			
any aspect of the s statistical analysis,	titution <b>at any time</b> recei ubmitted work (including etc.)? evant conflicts of intere	but not limited to gra				
	out the appropriate info		u have more than c	one entity pre	ess the "ADD	" button to add a row.
Excess rows can l	pe removed by pressing					
Name of Institut	ion/Company	Grant? Personal Fees?	Non-Financial Support?	Other ? Coi	mments	
Gilead Sciences				Empl	oyee	
Section 3.	Relevant financial	activities outside	the submitted w	ork.		
of compensation clicking the "Add	the appropriate boxes i ) with entities as descri +" box. You should rep evant conflicts of intere	bed in the instruction ort relationships the	ns. Use one line for	each entity;	add as many	lines as you need by
Section 4.	Intellectual Proper	ty Patents & Co	nvriahts			
Do you have any	patents, whether plan			t to the work	? Yes	✓ No

Doehle 2



Section 5. Relationships not severed above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Doehle reports personal fees from Gilead Sciences, during the conduct of the study; .

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Doehle 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether

earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Etzkorn 1



Section 1. Identifying Inform	mation							
1. Given Name (First Name) Kyle	2. Surname (Last Name) Etzkorn	3. Date 03-August-2015						
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Gregory Everson						
5. Manuscript Title Sofosbuvir with velpatasvir in treatment infection: a randomized trial	Sofosbuvir with velpatasvir in treatment-naïve cirrhotic and non-cirrhotic patients with genotype 1-6 hepatitis C virus							
6. Manuscript Identifying Number (if you k M15-1000	now it)							
Section 2. The Week Under C								
The Work Under C	Consideration for Public	cation						
Did you or your institution <b>at any time</b> receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?								
Are there any relevant conflicts of interest?								
Section 3. Relevant financial	activities outside the s	submitted work.						
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .  Are there any relevant conflicts of interest? Yes V No								
,								
Section 4. Intellectual Prope	rty Patents & Copyric	ghts						
Do you have any patents, whether plan	nned, pending or issued, br	oadly relevant to the work? Yes V No						

Etzkorn 2



Section 5.					
Section 5.	Relationships not covered above				
	relationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?				
Yes, the following relationships/conditions/circumstances are present (explain below):					
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest				
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements rnals may ask authors to disclose further information about reported relationships.				
Section 6.	Disclosure Statement				
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box				

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Etzkorn 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Wyles 1



laentifying	Information							
Section 1. Identifying Information								
1. Given Name (First Name) David	2. Surname (Last Name) Wyles	3. Date 03-August-2015						
4. Are you the corresponding auth	nor? Yes ✓ No	Corresponding Author's Name Gregory T. Everson						
5. Manuscript Title Sofosbuvir with velpatasvir in t infection: a randomized trial	reatment-naïve cirrhotic and non-c	cirrhotic patients with genotype 1-6 hepatitis C virus						
6. Manuscript Identifying Number M15-1000	(if you know it)							
Section 2. The Work U	Inder Consideration for Public	ation						
any aspect of the submitted work ( statistical analysis, etc.)?	(including but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ta monitoring board, study design, manuscript preparation,						
Are there any relevant conflicts	of interest? Yes No							
If yes, please fill out the approp Excess rows can be removed by		e more than one entity press the "ADD" button to add a row.						
Name of Institution/Company	Grant'	n-Financial Other? Comments						
		upport.						
Gilead Sciences	<b>✓</b>	Paid to UC Regents						
Section 2	nancial activities outside the s	Paid to UC Regents						
Section 3. Relevant fine Place a check in the appropriate of compensation) with entities	nancial activities outside the see boxes in the table to indicate whereas described in the instructions. Us nould report relationships that were of interest?	Paid to UC Regents						
Place a check in the appropriate of compensation) with entities clicking the "Add +" box. You sl Are there any relevant conflicts	e boxes in the table to indicate who as described in the instructions. Us nould report relationships that were of interest?   Yes No riate information below.  Grant? Personal Nor	Paid to UC Regents  submitted work.  ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by						
Place a check in the appropriate of compensation) with entities clicking the "Add +" box. You share there any relevant conflicts of the second	e boxes in the table to indicate whereas described in the instructions. Us nould report relationships that were of interest? Yes No priate information below.  Grant? Personal Nor	Paid to UC Regents  submitted work.  ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by se present during the 36 months prior to publication.  n-Financial Other? Comments						
Place a check in the appropriate of compensation) with entities clicking the "Add +" box. You share there any relevant conflicts If yes, please fill out the appropriate of Entity	e boxes in the table to indicate whereas described in the instructions. Us nould report relationships that were of interest? Yes No priate information below.  Grant? Personal Fees? St	Paid to UC Regents  submitted work.  ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by se present during the 36 months prior to publication.  n-Financial upport?  Comments						

Wyles 2



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments			
Bristol Myers Squibb	<b>√</b>				Paid to UC Regents			
Bristol Myers Squibb		$\checkmark$			Advisor/Consultant			
Merck	<b>✓</b>				Paid to UC Regents			
Janssen		$\checkmark$			Advisor/Consultant			
Tacere	<b>√</b>				Paid to UC Regents			
Section 4. Intellectual Propert	ty Pate	ents & Cop	oyrights					
Do you have any patents, whether plann	ned, pend	ing or issue	ed, broadly releva	nt to the	work? ☐ Yes   ✓ No			
Section 5. Relationships not o	overed	above						
Are there other relationships or activities potentially influencing, what you wrote i				influence	d, or that give the appearance of			
Yes, the following relationships/conc	ditions/cir	cumstance	s are present (exp	olain belo	ow):			
No other relationships/conditions/ci	rcumstan	ces that pre	esent a potential	conflict o	finterest			
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.								
Section 6. Disclosure Stateme	nt							
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.								
Dr. Wyles reports grants from Gilead Scie from AbbVie, personal fees from AbbVie from Merck, personal fees from Janssen,	e, grants f	rom Bristol	Myers Squibb, pe	ersonal fe	es from Bristol Myers Squibb, grants			

Wyles 3



#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Wyles 4



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

McHutchison 1



Section 1.	Identifying Inform	nation						
1. Given Name (Fi John	rst Name)	2. Surname (Last Nam McHutchison	ne)	3. Date 06-August-2015				
4. Are you the cor	responding author?	Yes ✓ No	Correspond	Corresponding Author's Name				
5. Manuscript Title Sofosbuvir with velpatasvir in treatment-naïve non-cirrhotic patients with genotype 1-6 hepatitis C virus infection: a randomized trial								
6. Manuscript Ider M15-1000	ntifying Number (if you kr	now it)						
	ı							
Section 2.	The Work Under Co	onsideration for Pu	ublication					
any aspect of the s statistical analysis, Are there any rel- If yes, please fill o	ubmitted work (including etc.)? evant conflicts of intere	y but not limited to gran est? Yes 1 prmation below. If you	ts, data monitoring No	g board, study design, ma	al, private foundation, etc.) for anuscript preparation,  ADD" button to add a row.			
Name of Institut	ion/Company	Grant? Personal Fees?	Non-Financial Support?	Other? Comments				
Gilead Sciences				<b>✓</b> Employment a	and stock			
Section 3.	Relevant financial	activities outside t	he submitted	work.				
of compensation clicking the "Add Are there any rel	) with entities as descri   +" box. You should rep evant conflicts of intere	ibed in the instruction port relationships that est? Yes 🕡 l	s. Use one line fo were <b>present d</b> No	or each entity; add as m	ips (regardless of amount nany lines as you need by <b>prior to publication</b> .			
Section 4.	Intellectual Proper	ty Patents & Cop	yrights					
Do you have any	patents, whether plan	ned, pending or issue	d, broadly releva	nt to the work?	es 🗸 No			

McHutchison 2



Section 5. Polationships not sovered above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Brainard reports other from Gilead Sciences, during the conduct of the study; .

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

McHutchison 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Han 1



Section 1.	Identifying Informa	ation						
1. Given Name (First Lingling	t Name)	2. Surname (Last Name) Han		3. Date 24-September-2015				
4. Are you the corre	esponding author?	Yes ✓ No	me					
5. Manuscript Title Sofosbuvir with velpatasvir in treatment-naïve non-cirrhotic patients with genotype 1-6 hepatitis C virus infection: a randomized trial.								
6. Manuscript Identi M15-1000	ifying Number (if you kno	ow it)	_					
Section 2.	The Work Under Co	nsideration for Public	cation					
Did you or your institution <b>at any time</b> receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?  Are there any relevant conflicts of interest?  Yes  No								
Section 3.	Polovant financial a	activities outside the	submitted work					
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .  Are there any relevant conflicts of interest? Yes Vo								
Section 4.	Intallactual Drawaut	ny Datanta & Canadi	white					
		ty Patents & Copyri						
Do you have any p	patents, whether plann	ed, pending or issued, br	roadly relevant to the work?	Yes ✓ No				

Han 2



Section 5. Relationships not severed above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Han has nothing to disclose.

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Han 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

TONG 1



Continu 1								
Section 1.	Identifying Inform	ation						
1. Given Name (Fi MYRON	rst Name)	2. Surname (Last Na TONG	ame)	3. Date 15-October-2015				
4. Are you the cor	4. Are you the corresponding author? ✓ Yes No							
5. Manuscript Title "Sofosbuvir with randomized trial	velpatasvir in treatmer	nt-na? non-cirrhotic	patients with genotype 1-6 h	nepatitis C virus infection: a				
•	ntifying Number (if you kn velpatasvir in treatmer		patien					
	I							
Section 2.	The Work Under Co	onsideration for	Publication					
Did you or your institution <b>at any time</b> receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?  Are there any relevant conflicts of interest?  Yes  No								
Section 3.	Relevant financial	activities outside	the submitted work.					
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .  Are there any relevant conflicts of interest? Yes Vo								
C 11 A								
Section 4.	Intellectual Proper	ty Patents & Co	ppyrights					
Do you have any	patents, whether plani	ned, pending or issu	ued, broadly relevant to the w	vork? Yes V No				

TONG 2



Section 5. Relationships not covered above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. TONG has nothing to disclose.

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

TONG 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent



	l								
Section 1.	Identifying Inform	nation							
1. Given Name (Fi Paul	rst Name)	2. Surname Thuluvath	=	e)		3. Date 03-August-2015			
4. Are you the cor	responding author?	Yes	<b>✓</b> No	-	Corresponding Author's Name Gregory Everson				
5. Manuscript Title Sofosbuvir with velpatasvir in treatment-naïve cirrhotic and non-cirrhotic patients with genotype 1-6 hepatitis C virus infection: a randomized trial									
6. Manuscript Ide M15-1000	ntifying Number (if you kr	now it)							
	I								
Section 2.	The Work Under C	onsideratio	on for Pu	blication					
	ubmitted work (including					ent, commercial, private foundation, etc.) for udy design, manuscript preparation,			
	evant conflicts of inter	est? ✓ Ye	s N	lo					
	out the appropriate info be removed by pressin			have more than	one enti	ity press the "ADD" button to add a row.			
excess fows carr	be removed by pressin	ے ا		Non-Financial	-				
Name of Institut	ion/Company	Grant•	ersonal Fees	Support?	Other •	Comments			
Gilead		<b>✓</b>							
				_					
Section 3.	Relevant financial	activities o	outside tl	he submitted	work.				
of compensation	n) with entities as descr	ibed in the ir	nstruction	s. Use oné line fo	or each er	cial relationships (regardless of amount ntity; add as many lines as you need by e 36 months prior to publication.			
•	evant conflicts of inter			lo					
If yes, please fill o	out the appropriate info	ormation bel	ow.						
Name of Entity		Grant	ersonal Fees	Non-Financial Support?	Other?	Comments			
Abbvie		<b>✓</b>			<b>√</b>	Speaker, Advisory Board			
Gilead		$\checkmark$			<b>✓</b>	Speaker, Advisory Board			
Salix		<b>✓</b>							



	_	Daysanal	Non-Financial				
Name of Entity	Grant?	Personal Fees?	Support?	Other •	Comments		
Tobira	<b>✓</b>		Баррогс				
Intercept	✓			✓	Advisory Board		
Galectin	<b>✓</b>						
Hologic	<b>✓</b>						
BMS				<b>✓</b>	Advisroy Board		
Section 4. Intellectual Propert	ty Pate	ents & Cop	pyrights				
Do you have any patents, whether plann	ed nend	ina or issue	ad broadly releva	nt to the	work? Yes ✓ No		
bo you have any pateries, whether plans	ica, peria	ing or issue	.u, broadly releva	iii to tiic	WOIK: TC3 7 140		
Section 5. Polationships not a							
Relationships not o	overed	above					
Are there other relationships or activities potentially influencing, what you wrote				nfluence	d, or that give the appearance of		
Yes, the following relationships/cond	ditions/cir	cumstance	es are present (exp	olain belo	ow):		
✓ No other relationships/conditions/cii							
<del></del>							
At the time of manuscript acceptance, jo On occasion, journals may ask authors to						ents.	
,					•		
Section 6. Disalogues Statoma							
Disclosure Stateme	nt						
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.							
below.							
Dr. Thuluvath reports grants from Gilead from Gilead, grants from Salix, grants fro Hologic, other from BMS, outside the su	om Tobira	, grants an	, -		_		



#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your

**Royalties:** Funds are coming in to you or your institution due to your patent



Section 1. Identifying Information	ation							
1. Given Name (First Name) Timothy	2. Surname (Last Name) Morgan		3. Date 06-August-2015					
4. Are you the corresponding author?	Yes No Corresponding Author's Name Everson, Greg							
5. Manuscript Title Sofosbuvir with velpatasvir in treatment-naïve cirrhotic and non-cirrhotic patients with genotype 1-6 hepatitis C virus infection: a randomized trial								
6. Manuscript Identifying Number (if you known M15-1000	ow it)							
Section 2. The Work Under Co	nsideration for Publi	ication						
Did you or your institution <b>at any time</b> received any aspect of the submitted work (including statistical analysis, etc.)?  Are there any relevant conflicts of interest fyes, please fill out the appropriate info Excess rows can be removed by pressing	but not limited to grants, d st?  Yes  No rmation below. If you ha	lata monitoring board, st	udy design, manuscript preparation,					
Name of Institution/Company	Grant? Personal No	on-Financial Other?	Comments					
Gilead	<b>✓</b>		Grant to my institution for participation in clinical trial					
Section 3. Relevant financial a	activities outside the	submitted work.						
Place a check in the appropriate boxes ir of compensation) with entities as described clicking the "Add +" box. You should rep	bed in the instructions. U	Jse one line for each er	ntity; add as many lines as you need by					
Are there any relevant conflicts of interesting the series of the series								
in yes, pieuse iiii out the appropriate iiiio	mation sciow.							
Name of Entity	Grant'	on-Financial Support?	Comments					
AbbVie	<b>V</b>		Grant to my institution for participation in clinical trial					
Bristol-Myers-Squibb	<b>✓</b>		Grant to my institution for participation in clinical trial					



Name of Entity	Grant?	Personal Fees	Non-Financial Support?	Other?	Comments				
Merck	<b>✓</b>				Grant to my institution for participation in clinical trial				
Genentech	$\checkmark$				Grant to my institution for participation in clinical trial				
Hoffmann LaRoche	<b>✓</b>				Grant to my institution for participation in clinical trial				
Section 4. Intellectual Propert	y Pate	ents & Cop	pyrights						
Do you have any patents, whether plann	ed, pend	ing or issue	ed, broadly releva	nt to the	work? ☐ Yes    ✓ No				
Section 5. Relationships not c	overed	above							
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?									
Yes, the following relationships/cond	litions/cir	cumstance	s are present (exp	olain belo	ow):				
✓ No other relationships/conditions/cir	cumstan	ces that pre	esent a potential o	conflict o	finterest				
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.									
Section 6. Disclosure Stateme	nt								
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.									
	Dr. Morgan reports grants from Gilead, during the conduct of the study; grants from AbbVie, grants from Bristol-Myers-Squibb, grants from Merck, grants from Genentech, grants from Hoffmann LaRoche, outside the submitted work; .								



#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Hinestrosa 1



Identifying Information

**Section 1.** 

# **ICMJE Form for Disclosure of Potential Conflicts of Interest**

1. Given Name (First Name) Federico	2. Surnar Hinestro	ne (Last Nan sa	ne)		3. Date 01-July-2015	
4. Are you the corresponding author?	Yes	<b>✓</b> No	Correspond	ding Autho	or's Name	
5. Manuscript Title Sofosbuvir with GS-5816 in treatment-naïve genotype 1-6 hepatitis C patients: a randomized, Phase 2 trial						
6. Manuscript Identifying Number (if you known M15-1000	ow it)					
Section 2. The Work Under Co	ncidora	tion for P	ublication			
Did you or your institution <b>at any time</b> receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?  Are there any relevant conflicts of interest?  Yes  No						
Section 3. Relevant financial activities outside the submitted work.						
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .						
Are there any relevant conflicts of interest?  Ves  No If yes, please fill out the appropriate information below.						
Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
Gilead	<b>✓</b>				Research	
BMS	<b>√</b>				Research	
Boehringer Ingelheim	<b>✓</b>				Research	
Abbvie	<b>✓</b>				Research	
/ertex	✓				Research	
Merck	<b>√</b>				Research	
lanssen	<b>√</b>				Research	

Hinestrosa 2



Section 4. Intellectual Property Patents & Copyrights
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo
Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Hinestrosa reports grants from Gilead, grants from BMS, grants from Boehringer Ingelheim, grants from Abbvie, grants from Vertex, grants from Merck, grants from Janssen, outside the submitted work;.

#### **Evaluation and Feedback**

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$ 

Hinestrosa 3